Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party

Bone Marrow Transplantation
L BentoS Montoto

Abstract

Relapse remains the most common cause of treatment failure in patients receiving autologous stem cell transplantation (ASCT) for follicular lymphoma (FL). The aim of this study was to evaluate the effect of adding radioimmunotherapy or rituximab (R) to BEAM (carmustine, etoposide, ara-c, melphalan) high-dose therapy for ASCT in patients with relapsed FL. Using the European Society for Blood and Marrow Transplantation registry, we conducted a cohort comparison of BEAM (n=1973), Zevalin-BEAM (Z-BEAM) (n=207) and R-BEAM (n=179) and also a matched-cohort analysis of BEAM vs Z-BEAM including 282 and 154 patients, respectively. BEAM, Z-BEAM and R-BEAM groups were well balanced for age, time from diagnosis to ASCT and disease status at ASCT. The cumulative incidences of relapse (IR) at 2 years were 34, 34 and 32% for Z-BEAM, R-BEAM and BEAM, respectively. By multivariate analysis, there were no significant differences with Z-BEAM or R-BEAM compared with BEAM for IR, non-relapse mortality, event-free survival or overall survival. With the caveat that the limitations of registry analyses have to be taken into account, this study does not support adding radioimmunotherapy or R to BEAM in ASCT for relapsed FL. However, we cannot rule out ...Continue Reading

References

May 23, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ama Z S RohatinerArnold S Freedman
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Myron S CzuczmanArturo Molina
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amrita KrishnanStephen J Forman
Oct 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Liliana DevizziAlessandro M Gianni
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck MorschhauserDavid M Goldenberg
Nov 24, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M GhielminiUNKNOWN Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma
Sep 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I El-NajjarUNKNOWN Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DreylingUNKNOWN ESMO Guidelines Committee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
I El-NajjarLymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
© 2022 Meta ULC. All rights reserved